Raj Prabhakar

Professional Background

Raj Prabhakar is a highly esteemed executive in the biotechnology sector, boasting over 20 years of extensive experience in viral vector, cell, gene, and vaccine therapy development. His career spans a broad spectrum of areas including rare diseases, oncology, immunotherapy, and the innovative realms of oligonucleotides and HSC stem cells. Raj has distinguished himself in ex-vivo (autologous cell and gene) and in-vivo (traditional drug and AAV gene therapy) development, with a particular focus on drug development in the emerging markets of the U.S., China, and the Asia-Pacific region. His comprehensive expertise underscores a deep understanding of the unique challenges and opportunities within these growing markets.

Raj's proficiency extends beyond drug development; he has significant operating experience in supply chain management and manufacturing within GMP (Good Manufacturing Practices) environments specific to cell processing, viral vector production, and plasmid production. His strategic engagement in sourcing, leading, and negotiating manufacturing and supply agreements for vital drug substances and products showcases his aptitude for ensuring efficient operational frameworks conducive to clinical success.

His impressive portfolio includes experience in in-and-out-licensing partnerships, fundraising, investor relations, and advisory roles, complemented by ventures in private equity and mergers and acquisitions. Raj is particularly noted for leading complex deal structures and negotiations, demonstrating a keen ability to navigate the intricacies of high-stake business transactions.

Education and Achievements

Raj Prabhakar received his MBA from the prestigious Harvard Business School, where he honed his expertise in strategic business management and leadership. Prior to his MBA, he completed a dual Bachelor of Science degree at the Massachusetts Institute of Technology (MIT), further establishing a robust academic foundation in scientific principles and methodologies pertinent to biopharma.

His professional journey is highlighted by several notable achievements:

• Instrumental in the successful execution of a multi-capsid AAV gene therapy license with REGENXBIO, showcasing his negotiation prowess and strategic insight.
• Secured licensing and development collaborations for the China and Japan territories—identified as the two largest markets for hepatocellular carcinoma (HCC) liver cancer indications. Raj deftly negotiated all terms including milestones, royalties, and development obligations, exemplifying his capability in international deal-making.
• Conducted a successful $105 million merger and acquisition of PCT to Hitachi Chemical (Japan), orchestrating a complex 2-stage transaction to integrate state-of-the-art global cell processing facilities.
• Led critical deal structuring efforts for long-term licensing and supply agreements with Zhejiang Hisun in the Greater China territory, fostering vital partnerships and business growth in a region ripe with potential.
• Spearheaded planning activities for product launches in the U.S., including product marketing and pricing strategies, patent protection, and life cycle management, underscoring his roles in translating innovative ideas into market realities.

Career Trajectory

Throughout his illustrious career, Raj has held several senior leadership positions across diverse organizations, showcasing his versatility and adaptability in dynamic environments. Currently, he serves as the Chief Business Officer and Senior Vice President at Rocket Pharmaceuticals, where he is integral to driving the company’s strategic initiatives and business development efforts. His previous role as Senior Vice President of Business Development at Caladrius Biosciences further enhanced his industry standing, allowing him to leverage his expertise in commercialization and partnerships.

Prior to these pivotal roles, Raj was the Senior Commercialization Officer for Vaccines at the PATH Global Vaccine Development Program, where he contributed significantly to vaccine innovations aimed at global public health challenges. His strategic leadership as Vice President of Business Development while at Celsion Corporation and in earlier roles solidified his reputation as a trusted leader capable of steering companies to new heights of success. Raj's journey includes impactful contributions as Director of Corporate Development at Protiveris and as Assistant to the CEO and Director of Corporate Development at Osiris Therapeutics, where he played pivotal roles in shaping company strategies.

Raj's early career included an associate position at Vertex Venture Management Pte Ltd and a role in private equity at Swander Pace Capital, providing him with a rich background in financial structuring and investments, crucial skills that complement his acumen in biopharmaceutical development.

Conclusion

Raj Prabhakar has firmly established himself as a leader in biotechnology, adept at navigating complex landscapes within viral vectors, gene and cell therapies, and vaccine development. His extensive operational experience, coupled with his strategic insights and remarkable negotiation skills, has positioned him at the forefront of the industry. With a track record that speaks volumes, Raj continues to be an influential figure dedicated to advancing biopharma innovation and contributing to critical health care solutions globally.